Compositions and methods for treatment or prevention of;infections and for the eradication or reduction of;on surfaces

• US 9,107,419 B2
• Filed: 01/06/2010
• Issued: 08/18/2015
• Est. Priority Date: 01/06/2009
• Status: Active Grant

• Current Assignee: Galenagen, LLC
• Original Assignee: Curelon LLC
• Inventors: Fallon, Joan M., Heil, Matthew, Fallon, James J.
• Primary Examiner(s): Carlson, Karen Cochrane
• Assistant Examiner(s): Tichy, Jennifer M. H.
• Application Number:
  US13/144,286
• Publication Number:
  US 20110280853A1
• Time in Patent Office: 2,050 Days
• Field of Search: 424/94.2
• US Class Current: 1/1
• CPC Class Codes: A01N 63/50 Isolated enzymes; Isolated proteins peptides A01N37/46
• CPC Class Codes: A01N 65/00 Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof containing compounds of determined constitution A01N27/00 - A01N59/00
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/465 acting on ester bonds (3.1), e.g. lipases, ribonucleases
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61K 38/4826 Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
• CPC Class Codes: A61K 38/54 Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61L 2/0088 Liquid substances
• CPC Class Codes: A61L 2/18 Liquid substances or solutions comprising solids or dissolved gases
• CPC Class Codes: A61L 2/22 Phase substances, e.g. smokes, aerosols or sprayed or atomised substances
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/02 Local antiseptics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C11D 3/386 Preparations containing enzymes , e.g. protease or amylase
• CPC Class Codes: C11D 3/38627 containing lipase
• CPC Class Codes: C11D 3/38636 containing enzymes other than protease, amylase, lipase, cellulase, oxidase or reductase
• CPC Class Codes: C12Y 301/01 : Carboxylic ester hydrolases (3.1.1)
• CPC Class Codes: C12Y 302/01 : Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
• CPC Class Codes: C12Y 304/21001 : Chymotrypsin (3.4.21.1)
• CPC Class Codes: C12Y 304/21004 : Trypsin (3.4.21.4)

Abstract

Compositions and methods for treating or preventing S. aureus infections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduce S. aureus populations and thereby treat or prevent infection by S. aureus. The compositions include one or more digestive enzymes, e.g., one or more protease, lipases, and amylases. Methods of use of the compositions are also provided.

Claims

1. A method for the treatment or prevention of Staphylococcus aureus infection in a bird or a mammal, comprising administering to the bird or mammal a therapeutically effective amount of an oral pharmaceutical composition comprising digestive enzymes and a pharmaceutically acceptable excipient, wherein the digestive enzymes comprise a protease, an amylase, and a lipase, wherein the pharmaceutical composition is bacteriocidal or bacteriostatic for Staphylococcus aureus, wherein the pharmaceutical composition is formulated for oral administration, and wherein a ratio of total protease to total lipase ranges from about 1:

1 to about 20;

1.

2. The method of claim 1, wherein the digestive enzymes comprise pancreatic enzymes.

3. The method of claim 1, wherein the digestive enzymes comprise pig enzymes.

4. The method of claim 1, wherein the protease comprises chymotrypsin and trypsin.

5. The method of claim 1, wherein the digestive enzymes are, independently, derived from an animal source, a microbial source, a plant source, or a fungal source, or are synthetically prepared.

6. The method of claim 1, wherein the mammal is a pig, horse, cow, dog, cat, monkey, rat, mouse, sheep, goat, or human, and wherein the bird is a chicken, duck, turkey, or goose.

7. The method of claim 5, where the animal source is a pig pancreas.

8. The method of claim 1, wherein the ratio of total protease to total lipase ranges from about 4:

1 to about 10;

1.

9. The method of claim 1, wherein the pharmaceutical composition is a dosage formulation selected from the group consisting of:

pills, tablets, capsules, caplets, sprinkles, emulsions, powders, liquids, gels, and a combination of any thereof.

10. The method of claim 1, further comprising administering a beta-lactam antibiotic to the bird or mammal.

11. The method of claim 1, wherein the ratio of total protease to total lipase is about 4:

1.

12. The method of claim 1, wherein the ratio of total protease to total lipase is about 5:

1.

13. The method of claim 1, wherein the ratio of total protease to total lipase is about 7:

1.

14. The method of claim 1, wherein the ratio of total protease to total lipase is about 10:

1.

15. The method of claim 1, wherein the ratio of total protease to total lipase is about 12:

1.

16. The method of claim 1, wherein the pharmaceutical composition comprises about 200 USP units/mg of protease, about 40 USP units/mg of lipase, and about 250 USP units/mg of amylase.